Atlas Venture Fund X, L.P., 10% Owner at Kymera Therapeutics, Inc. (KYMR), sold 485,310 shares at $30.57 ($14.7M) on 2022-11-01, disclosed to the SEC on 2022-11-01.
Scheduled sale ($14.7M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.00 | 19,915 | $597K | 4.1% |
| 2 | $30.00 | 71,135 | $2.1M | 14.5% |
| 3 | $30.23 | 26,383 | $798K | 5.4% |
| 4 | $30.23 | 26,383 | $798K | 5.4% |
| 5 | $30.23 | 94,239 | $2.8M | 19.4% |
| 6 | $30.23 | 94,239 |
| $2.8M |
| 19.4% |
| 7 | $30.57 | 56,455 | $1.7M | 11.7% |
| 8 | $30.57 | 15,804 | $483K | 3.3% |
| 9 | $30.57 | 15,804 | $483K | 3.3% |
| 10 | $30.57 | 56,455 | $1.7M | 11.7% |
| 11 | $31.08 | 3,727 | $116K | 0.8% |
| 12 | $31.08 | 3,727 | $116K | 0.8% |
| 13 | $31.08 | 1,044 | $32K | 0.2% |
| Total | $30.30 avg | 485,310 | $14.7M | 100% |
| Filing → |